Definitive Contract HHSN261201400028C

<p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a &quot;fibrous scaffold-induced spheroids mimicking TME&quot; solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>

This is a $225,000.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a Minority Owned, For Profit, Subcontinent Asian (Asian-Indian) American Owned business. The contract is for &quot;SBIR PHASE I - FISS-CSC: A FIBER-INSPIRED SMART SCAFFOLD PLATFORM FOR EXPANDING CANCER STEM CELLS&quot; and was awarded on September 22, 2015 with a completion date of August 21, 2016. This appears to be a Small Business Innovation Research...

This federal contract award to Genscript USA Inc., a biotechnology company, is for the provision of laboratory services to detect mutation-reactive T cells in patients with metastatic cancers. The contract was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services National Institutes of Health, and has a potential value of $250,000.00. This is a follow-on effort to a previous contract awarded in 2017. The contract has no set-aside designation. Under...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This federal contract award, with ID HHSN261201300042C, was issued by the National Cancer Institute, a civilian agency, to Trevigen, Inc., a for-profit manufacturer. The contract is for a Small Business Innovation Research (SBIR) Phase I project on a &quot;Tumor-Aligned Coculture System&quot;, with a ceiling value of $252,272. The contract is a definitive, firm-fixed-price contract with a completion date of July 18, 2014. Trevigen, Inc. is the prime contractor, and the award is designated as a...

The National Cancer Institute awarded a $6,176 firm fixed-price blanket purchase agreement call to Transnetyx, Inc. for genotyping of alleles from tail samples. The contract was executed on August 17, 2018, with an ultimate completion date of March 14, 2023, and performance is based in Cordova, Tennessee. This award utilized no set-aside designation, indicating open market competition. The contract was issued to de-obligate expiring fiscal year 2018 funds in accordance with NIH Office of...

This is a $299,654 firm fixed price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Pgxl Technologies LLC, a minority-owned limited liability company. The contract, titled &quot;DETECTION, ISOLATION, AND ANALYSIS OF SINGLE CTCS,&quot; has a completion date of September 12, 2014 and does not appear to have a set-aside designation. The contract is for the detection, isolation, and analysis of single circulating tumor cells (CTCs). Pgxl Technologies LLC is the...

<p>The National Cancer Institute awarded a purchase order to 10X Genomics, Inc. for $7,849.00 in bio products on December 12, 2017, with an ultimate completion date of January 12, 2018. Work is performed in Pleasanton, California. The order is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to 10X Genomics, Inc. for reagents valued at $23,221 on August 26, 2019, with completion by September 22, 2019. Performance occurs in Pleasanton, California. The order is firm fixed price with no set-aside used.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $3 million firm fixed price purchase order to 10X Genomics, Inc. for genomics products and services. As the prime contractor, 10X Genomics will deliver its genome sequencing platforms and assays to support the agency's cancer research efforts from its Pleasanton, California location through the end of 2023. No subcontractors or set aside designations were indicated. This award draws on...